lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
On 1 May 1999 Pudzianowski entered his first Strongman competition, held in Płock, Poland. He achieved his first major success at the international level at the 2000 World's Strongest Man contest where he finished fourth in his first WSM competition. Due to his prison sentence, he did not return for the 2001 competition. Pudzianowski returned at the 2002 World's Strongest Man and won his first title. He retained his title at the 2003 World's Strongest Man with an event to spare, winning by the largest margin ever achieved in the competition; across the seven disciplines in the final, he scored a remarkable four first place finishes, two second place finishes and one third place finish, resulting in the points margin between first and second (20) being greater than the margin between second and ninth (18). British strongman Laurence Shahlaei has since called this performance the most dominant victory ever seen at a World's Strongest Man event. In March 2004, he also became the Strongman Super Series World Champion. He initially finished third in the 2004 World's Strongest Man but was later disqualified for breaching the governing body's Strongman Health Policy. He was forced to return his prize money, stripped of the International Federation of Strength Athletes points from the event, and received a one-year ban from competition. Pudzianowski did not dispute his banned substance violation and waived his right to have his stool sample verified. In 2005, he made his return to World's Strongest Man event.
Nanotechnology offers the potential of novel nanomaterials for the treatment of surface water, groundwater, wastewater, and other environmental materials contaminated by toxic metal ions, organic and inorganic solutes, and microorganisms. Due to their unique activity toward recalcitrant contaminants, many nanomaterials are under active research and development for use in the treatment of water and contaminated sites. The present market of nanotech-based technologies applied in water treatment consists of reverse osmosis(RO), nanofiltration, ultrafiltration membranes. Indeed, among emerging products one can name nanofiber filters, carbon nanotubes and various nanoparticles. Nanotechnology is expected to deal more efficiently with contaminants which convectional water treatment systems struggle to treat, including bacteria, viruses and heavy metals. This efficiency generally stems from the very high specific surface area of nanomaterials, which increases dissolution, reactivity and sorption of contaminants.
The party says those involved will no longer be involved in the election campaign. Prominent Conservative donor Sir John Hall endorses Reform UK. The final televised debate of the 2024 general election takes place on BBC One Northern Ireland and features representatives from Northern Ireland's five main parties. Labour lifts its suspension of Rhianon Passmore after police say they had found no offence was committed regarding the number plates on her car. 28 June – Sunak speaks of his hurt and anger at his daughters having to hear a racial slur used about him by Reform UK activists. Essex Police say they are urgently trying to establish whether any criminal offences have been committed as a result of comments made by the Reform campaigners. Mark Hoath, the Reform UK candidate for Sutton Coldfield, is referred to the police after saying that a rival candidate, the Liberal Democrats' John Sweeney, "loved" the IRA. Edinburgh City Council establishes an emergency polling booth at City Chambers after a number of people across Scotland reported not receiving their postal votes. The emergency polling booth, which allows those who did not receive a postal vote to cast their vote in person, will operate until 30 June. Fife Council also announces an emergency polling booth at Fife House, Glenrothes that will be open on 29 June. The Green Party of Northern Ireland launches its manifesto, which includes plans to take Lough Neagh into public ownership, reforms to Stormont, a tax on the richest one percent of people and protecting public services from cuts.
Sources: en.wikipedia.org
Cmax: Maximum serum concentration that the drug achieves in the body after the drug has been administered tmax: Time to achieve maximum plasma concentration t1/2: Biological half-life In studies that were made on healthy people and people with type 2 diabetes, who were given dapagliflozin in either single ascending dose (SAD) or multiple ascending dose (MAD) showed results that confirmed a pharmacokinetic profile of the medication. With dose-dependent concentrations the half-life is about 12–13 hours, Tmax 1–2 hours and it is protein-bound, so the medication has a rapid absorption and minimal excretion by the kidney. Dapagliflozin disposition is not evidently affected by body mass index (BMI) or body weight, therefore, the pharmacokinetic findings are expected to be applicable to patients with a higher BMI. Dapagliflozin resulted in dose-dependent increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its mechanism of action. Some studies found that dapagliflozin is associated with a decrease in body weight, which is statistically superior compared to placebo or other active comparators. It is primarily associated with caloric rather than fluid loss. In contrast with other anti-hyperglycemic diabetes medications, SGLT2 inhibitors enhance, rather than suppress, gluconeogenesis and ketogenesis. Because SGLT2 inhibitors activate sirtuin 1 (and thus PGC-1α and FGF21), they are more cardioprotective than the other medications used to treat diabetes.
== Structure == Most sv-LAAOs are reported as being homodimers with multiple subunits that have molecular weights around 50–70 kDa and the interaction between the subunits occurs via non-covalent interactions. Sv-LAAOs are present in the acidic, basic, and neutral forms of the protein. Studies that look at x-ray crystal structures have confirmed that sv-LAAOs are often found as functional dimers, with each dimer having three domains. The three domains are the substrate-binding site, FAD-binding site, and a helical domain. The substrate-binding site lies at the bottom of a funnel-shaped cavity approximately 25 Å deep, enabling substrate specificity among sv-LAAOs. Structural differences in active site topology likely account for species-dependent substrate preferences. Additionally, LAAOs are thermolabile, with cold inactivation and heat reactivation properties, necessitating specific storage and pre-activation conditions to preserve enzymatic activity. It has also been determined that the FAD prosthetic group becomes deeply entrenched in the enzyme structure, which allows for pervasive interactions with both neighboring atoms and conserved water molecules. Additionally, this flavin-containing prosthetic group has been classified as providing snake venom with its quintessential dark yellow coloration, which is shown in Figure 2. One unusual characteristic reported for sv-LAAOs regards the cold inactivation and heat reactivation properties of the protein. Thereby, most sv-LAAOs are considered to be thermolabile enzymes.
=== STF === West Bengal government created new directorate of the Special Task Force under West Bengal Police. The Special Task Force (STF) of West Bengal, formed around three years ago, to combat modern urban organized crimes - terrorism, organized gangs, illegal arms, ammunition, drugs and fake currency across the state is all set to get a police station of its own and a designated court.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.